NFL Biosciences SA (ALNFL.PA)
EUR 1.88
(-2.59%)
EUR 1.88
(-2.59%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | 56.06 Thousand | 2.23 Million | 530.73 Thousand | 169.35 Thousand | 253.87 Thousand |
| Gross Profit | -56.06 Thousand | -2.23 Million | -530.73 Thousand | -169.35 Thousand | -253.87 Thousand |
| Operating Expenses | 4.37 Million | 668.95 Thousand | 588.76 Thousand | 148.67 Thousand | 93.42 Thousand |
| Selling, General and Administrative Expenses | 4.36 Million | 2.95 Million | 808.61 Thousand | 274.73 Thousand | - |
| Research and Development Expenses | - | - | - | - | - |
| Other Expenses | -4670.00 | 668.95 Thousand | 588.76 Thousand | 148.67 Thousand | 93.42 Thousand |
| Cost and Expenses | 4.43 Million | 2.9 Million | 1.11 Million | 318.03 Thousand | 347.29 Thousand |
| Operating Income | -4.43 Million | -3.08 Million | -901.86 Thousand | -318.02 Thousand | -347.29 Thousand |
| Interest Expense | - | 493.00 | 538.00 | - | 376.00 |
| Income Tax Expense | -366.39 Thousand | -417.82 Thousand | -141.26 Thousand | -51.54 Thousand | -79.71 Thousand |
| Earnings before Tax | -4.11 Million | -2.86 Million | -1.11 Million | -318.03 Thousand | -347.67 Thousand |
| Net Income | -3.74 Million | -2.44 Million | -978.24 Thousand | -266.48 Thousand | -267.96 Thousand |
| Earnings Per Share Basic | -0.46 | -0.47 | -0.19 | -0.05 | -0.05 |
| Earnings Per Share Diluted | -0.46 | -0.47 | -0.19 | -0.05 | -0.05 |
| Weighted Average Shares Outstanding | 8.1 Million | 5.23 Million | 5.23 Million | 5.23 Million | 5.23 Million |
| Weighted Average Shares Outstanding (Diluted) | 8.1 Million | 5.23 Million | 5.23 Million | 5.23 Million | 5.23 Million |
| Gross Margin | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - |
| Profit Margin | - | - | - | - | - |
| EBITDA | -4.04 Million | -2.8 Million | -1.07 Million | -271.09 Thousand | -303.6 Thousand |
| Earnings Before Tax Margin | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q2 | 2022 Q4 | 2022 FY |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 25.91 Thousand | 56.06 Thousand | 27.3 Thousand | 28.75 Thousand | 26.7 Thousand | 2.23 Million |
| Gross Profit | -25.91 Thousand | -56.06 Thousand | -27.3 Thousand | -28.75 Thousand | -26.7 Thousand | -2.23 Million |
| Operating Expenses | 870.15 Thousand | 4.37 Million | 1.92 Million | 2.44 Million | 1.71 Million | 668.95 Thousand |
| Selling, General and Administrative Expenses | 867.87 Thousand | - | 1.92 Million | 2.44 Million | 1.71 Million | - |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | -2280.00 | -4670.00 | -1920.00 | -2760.00 | -1860.00 | 668.95 Thousand |
| Cost and Expenses | 896.06 Thousand | 4.43 Million | 1.95 Million | 2.47 Million | 1.73 Million | 2.9 Million |
| Operating Income | -896.06 Thousand | -4.43 Million | -1.95 Million | -2.47 Million | -1.73 Million | -3.08 Million |
| Interest Expense | 142.00 | - | - | 229.00 | 247.00 | 493.00 |
| Income Tax Expense | -121.77 Thousand | -366.39 Thousand | -166.04 Thousand | -200.34 Thousand | -296.19 Thousand | -417.82 Thousand |
| Earnings before Tax | -853.28 Thousand | -4.11 Million | -1.8 Million | -2.31 Million | -1.66 Million | -2.86 Million |
| Net Income | -731.5 Thousand | -3.74 Million | -1.63 Million | -2.11 Million | -1.37 Million | -2.44 Million |
| Earnings Per Share Basic | -0.08 | - | -0.20 | -0.28 | -0.26 | - |
| Earnings Per Share Diluted | -0.08 | - | -0.20 | -0.28 | -0.26 | - |
| Weighted Average Shares Outstanding | 9.7 Million | 8.1 Million | 8.1 Million | 7.6 Million | 5.23 Million | 5.23 Million |
| Weighted Average Shares Outstanding (Diluted) | 9.7 Million | 8.1 Million | 8.1 Million | 7.6 Million | 5.23 Million | 5.23 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -827.23 Thousand | - | -1.92 Million | -2.44 Million | -1.71 Million | - |
| Earnings Before Tax Margin | - | - | - | - | - | - |
8147
IMMP
2139
6371
OMEX
QZMRF